Sachs David C. has filed 30 insider transactions across 1 company since December 2022.
Most recent transaction: a option exercise of 40650 shares of ImmunityBio, Inc. ($IBRX) on February 22, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 22, 2026 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 40650 | $0.00 | 40,651.0000 | 984,965,179 | 50.00% | 0.00% |
| Feb. 22, 2026 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 40650 | $0.00 | 320,825.0000 | 984,965,179 | 14.51% | 0.00% |
| Feb. 22, 2026 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 20682 | $8.70 | 300,143.0000 | 984,965,179 | 6.45% | 0.00% |
| Feb. 10, 2026 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 82236 | $0.00 | 322,818.0000 | 984,965,179 | 34.18% | 0.01% |
| Feb. 10, 2026 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 82236 | $0.00 | 164,474.0000 | 984,965,179 | 33.33% | 0.01% |
| Feb. 10, 2026 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 42643 | $6.93 | 280,175.0000 | 984,965,179 | 13.21% | 0.00% |
| Dec. 31, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 30397 | $0.00 | 45,602.0000 | 984,965,179 | 40.00% | 0.00% |
| Dec. 31, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 30397 | $0.00 | 256,017.0000 | 984,965,179 | 13.47% | 0.00% |
| Dec. 31, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 15435 | $1.98 | 240,582.0000 | 984,965,179 | 6.03% | 0.00% |
| Feb. 22, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 40650 | $0.00 | 241,480.0000 | 852,904,340 | 20.24% | 0.00% |
| Feb. 22, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 15860 | $3.42 | 225,620.0000 | 852,904,340 | 6.57% | 0.00% |
| Feb. 22, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 40650 | $0.00 | 81,301.0000 | 852,904,340 | 33.33% | 0.00% |
| Feb. 10, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | A | Stock Option (right to buy) | 843750 | $0.00 | 843,750.0000 | 852,904,340 | 9999.99% | 0.10% |
| Feb. 10, 2025 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | A | Restricted Stock Units | 246710 | $0.00 | 246,710.0000 | 852,904,340 | 9999.99% | 0.03% |
| Dec. 31, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 30397 | $0.00 | 216,235.0000 | 696,831,296 | 16.36% | 0.00% |
| Dec. 31, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 15405 | $2.56 | 200,830.0000 | 696,831,296 | 7.12% | 0.00% |
| Dec. 31, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 30397 | $0.00 | 75,999.0000 | 696,831,296 | 28.57% | 0.00% |
| Feb. 22, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | A | Stock Option (right to buy) | 424390 | $0.00 | 424,390.0000 | 670,867,344 | 9999.99% | 0.06% |
| Feb. 22, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | A | Restricted Stock Units | 121951 | $0.00 | 121,951.0000 | 670,867,344 | 9999.99% | 0.02% |
| Jan. 31, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 26835 | $3.36 | 185,838.0000 | 670,867,344 | 12.62% | 0.00% |
| Jan. 31, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 70745 | $0.00 | 0.0000 | 670,867,344 | 100.00% | 0.01% |
| Jan. 31, 2024 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 70745 | $0.00 | 212,673.0000 | 670,867,344 | 49.85% | 0.01% |
| Dec. 31, 2023 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 30397 | $0.00 | 152,439.0000 | 421,569,115 | 24.91% | 0.01% |
| Dec. 31, 2023 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 30397 | $0.00 | 106,396.0000 | 421,569,115 | 22.22% | 0.01% |
| Dec. 31, 2023 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | F | Common Stock | 10511 | $5.02 | 141,928.0000 | 421,569,115 | 6.90% | 0.00% |
| Sept. 1, 2023 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 70744 | $0.00 | 70,745.0000 | 421,569,115 | 50.00% | 0.02% |
| Sept. 1, 2023 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 70744 | $0.00 | 122,042.0000 | 421,569,115 | 137.91% | 0.02% |
| Aug. 25, 2023 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | A | Restricted Stock Units | 141489 | $0.00 | 141,489.0000 | 421,569,115 | 9999.99% | 0.03% |
| Dec. 31, 2022 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Restricted Stock Units | 7598 | $0.00 | 136,793.0000 | 397,830,044 | 5.26% | 0.00% |
| Dec. 31, 2022 | ImmunityBio, Inc. | $IBRX | Sachs David C. | Chief Financial Officer | M | Common Stock | 7598 | $0.00 | 51,298.0000 | 397,830,044 | 17.39% | 0.00% |